Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nelitolimod (SD-101) via PRVI in Locally Advanced Pancreatic Cancer
NCT05607953Phase 1Active, not recruiting
- Sponsor
- TriSalus Life Sciences
- Start
- Mar 2023
- Primary completion
- Sep 2027
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 1, open-label trial of nelitolimod in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by TriSalus Life Sciences. Primary endpoints: Maximum Tolerated Dose or Optimal Biologic Dose at 12 months, Safety and Tolerability at 12 months and 1 more. Started Mar 2023; status: active, not recruiting.
02
Drugs
nelitolimod
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05607953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05607953.